The acknowledgment that asthma is a heterogeneous disease has prompted pharmaceutical companies to develop new drugs to specifically target eosinophils, IL-5, IL4 receptor, and IgE involved in different types of asthma [11]. The gene discussed is IGHE; the disease is asthma.